Lucas Chan, Scientific Founder and CSO of CellVec, a Singapore-based CDMO that specializes in the development and manufacture of viral vectors for clinical gene therapy, discusses how his company is helping companies with mature preclinical gene therapy projects wanting to progress into the clinic. Moreover, he discusses why Singapore is a good strategic place to launch regenerative therapy projects, and how CellVec can help reduce manufacturing and development costs in an area that so badly needs it.
Cell and gene therapy is a highly collaborative field and its successful deployment necessitates CellVec to build close working partnerships with others across the entire ecosystem.
